Survivin in lung cancer: a potential target for therapy and prevention-a narrative review

被引:5
作者
Pachimatla, Akhil Goud [1 ]
Fenstermaker, Robert [2 ,3 ]
Ciesielski, Michael [2 ]
Yendamuri, Sai [1 ,3 ]
机构
[1] Roswell Park Comprehens Canc Ctr, Dept Thorac Surg, CSC 715,Elm & Carlton St, Buffalo, NY 14263 USA
[2] Roswell Park Comprehens Canc Ctr, Dept Neurosurg, Buffalo, NY 14263 USA
[3] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA
关键词
Survivin; lung cancer; carcinogenesis; chemoresistance; vaccines; GROWTH-FACTOR RECEPTOR; ANTI-APOPTOSIS GENE; DOWN-REGULATION; DRUG-RESISTANCE; EXPRESSION; CELLS; PROTEIN; ACTIVATION; INHIBITION; NUCLEAR;
D O I
10.21037/tlcr-23-621
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objective: A versatile biomarker, survivin, is highly expressed in proliferating cells of multiple cancers in humans and animals. It is an apoptosis-regulating protein, engaging in a cascade of reactions that involve several other genes and protein interactions. Currently, researchers are investigating its therapeutic potential due to the evidence linking its overexpression to advanced -stage lung cancer. This review is centered around examining survivin-related molecular mechanisms and its therapeutic role specifically in lung cancer. Our objective is to discuss the role of survivin in prognosis and treatment response, shedding light on immune -targeted therapies, as well as outlining future directions for survivinbased vaccines in lung cancer. Methods: The PubMed database and the United States National Library of Medicine search engine at the National Institutes of Health were searched on 24 August 2023 to identify published research studies. Searching "((((((airway [Title/Abstract]) OR (lung [Title/Abstract])) OR (pulm[Title/Abstract])) OR (bronch[Title/Abstract])) OR (nslc[Title/Abstract])) AND (((cancer[Title/Abstract]) OR (carcino[Title/ Abstract])) OR (oncol[Title/Abstract]))) AND (survivin[Title/Abstract])" gave 728 results. After screening the title and abstracts and excluding the review articles 168 titles were shortlisted and full text studied. The discussions are added to relevant sections. Key Content and Findings: Survivin is a cell cycle -dependent, inhibitor of apoptosis protein that contributes to carcinogenesis, tumor vascularization, metastasis, and treatment resistance. Several treatments that impact survivin either directly or indirectly have been reported as effective in treating lung cancer. Immunity -based therapy, a novel approach known for its targeted nature and minimal side effects, is currently under investigation for lung cancer treatment. Emerging survivin-centered vaccines exhibit promising attributes in terms of safety, effectiveness, and ability to stimulate an immune response. These factors point towards a significant potential for advancing the future of lung cancer prevention and enhancing overall survival rates. Conclusions: Nuclear survivin is a potential biomarker for advanced non -small cell lung cancer. It plays a role in determining drug responsiveness and is found to be significantly elevated in cases of resistance to chemotherapy. Multiple compounds and immunization strategies have been identified to impact lung cancer cells; however, they are currently in the early stages of phase I or phase II clinical trials. The substantial promise of survivin-based immunogenicity-focused treatments warrants in-depth investigation and exploration.
引用
收藏
页码:362 / 374
页数:13
相关论文
共 50 条
  • [41] Vitamin D: Potential in the Prevention and Treatment of Lung Cancer
    Norton, Rosemary
    O'Connell, Maria A.
    ANTICANCER RESEARCH, 2012, 32 (01) : 211 - 221
  • [42] Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis
    Sun, Ting
    Zhang, Penghua
    Zhang, Qingyi
    Wang, Binhui
    Zhao, Qitai
    Liu, Fenghui
    Ma, Xiaohua
    Zhao, Chunling
    Zhou, Xiaolei
    Chen, Ruiying
    Ouyang, Songyun
    HELIYON, 2024, 10 (10)
  • [43] Cancer stem cell metabolism: a potential target for cancer therapy
    Deshmukh, Abhijeet
    Deshpande, Kedar
    Arfuso, Frank
    Newsholme, Philip
    Dharmarajan, Arun
    MOLECULAR CANCER, 2016, 15
  • [44] Hypoxia A Typical Target in Human Lung Cancer Therapy
    Ullah, Asmat
    Shehzadi, Somia
    Ullah, Najeeb
    Nawaz, Touseef
    Iqbal, Haroon
    Aziz, Tariq
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2024, 25 (05) : 376 - 385
  • [45] Promising preclinical models for lung cancer research-lung cancer organoids: a narrative review
    Chen, Xinru
    Ye, Li
    Wang, Hao
    Liu, Xinyue
    Zhao, Lishu
    Xu, Kandi
    Liu, Yujin
    He, Yayi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (03) : 623 - 634
  • [46] CSN6: a promising target for cancer prevention and therapy
    Hou, Jianbing
    Cui, Hongjuan
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (07) : 645 - 652
  • [47] The combination astemizole-gefitinib as a potential therapy for human lung cancer
    de Guadalupe Chavez-Lopez, Maria
    Zuniga-Garcia, Violeta
    Hernandez-Gallegos, Elisabeth
    Vera, Eunice
    Alexandra Chasiquiza-Anchatuna, Carmen
    Viteri-Yanez, Marco
    Sanchez-Ramos, Janet
    Garrido, Efrain
    Camacho, Javier
    ONCOTARGETS AND THERAPY, 2017, 10 : 5795 - 5803
  • [48] The down-regulated ING5 expression in lung cancer: A potential target of gene therapy
    Zhao, Shuang
    Yang, Xue-feng
    Shen, Dao-fu
    Gao, Yang
    Shi, Shuai
    Wu, Ji-cheng
    Liu, Hong-xu
    Sun, Hong-zhi
    Su, Rong-jian
    Zheng, Hua-chuan
    ONCOTARGET, 2016, 7 (34) : 54596 - 54615
  • [49] Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy
    Ichiki, Y
    Hanagiri, T
    Takenoyama, M
    Baba, T
    Fukuyama, T
    Nagata, Y
    Mizukami, M
    So, T
    Sugaya, M
    Yasuda, M
    So, T
    Sugio, K
    Yasumoto, K
    LUNG CANCER, 2005, 48 (02) : 281 - 289
  • [50] Recent Advances of Novel Therapeutic Agents from Botanicals for Prevention and Therapy of Breast Cancer: An Updated Review
    Singh, Namrata
    Kushwaha, Poonam
    Amresh, Gupta
    Prakash, Om
    CURRENT CANCER THERAPY REVIEWS, 2020, 16 (01) : 5 - 18